What makes this candidate ideal is that it is an antibody-drug conjugate [ADC] that targets DLL3-expressing solid tumors. Two Catalysts In 2025 For ADC Candidate Could Launch Another Solid Program ...

The posters cover the Company’s new payload class, the ProAlk series, its CA242-directed ADC, IKS04, being developed for the treatment of gastrointestinal (GI) cancers, and its proprietary ...

WORCESTER, England, April 01, 2025--(BUSINESS WIRE)--JointMedica, a global leader in orthopedic innovation, announces the commencement of an Investigational Device Exemption (IDE) study for its ...

Students should know that both university websites are loading slowly. If students are unable to check their scores right away, they should wait some time and try again later. Also read: Goa HSSC ...

The findings were presented at the 15 th World ADC London 2025, taking place from March 3 to 6 at Novotel London West, London, UK. “We are excited to share groundbreaking data on SOT109 ...

Lately, the blood cancer drug has been overshadowed by another ADC from the legacy Seagen portfolio, the Nectin-4-targeted Padcev. Thanks to a first-line approval in bladder cancer, Padcev’s ...

The ADC 104th Annual Awards, the world’s longest continuously running awards program celebrating design and craft excellence, has launched its call for entries alongside a striking new campaign ...

The partners will work on IBI3009, a DLL3-targeted ADC that has been cleared for clinical trials in the U.S. and China. The first patient with small cell lung cancer was dosed in a Phase I trial in ...

Introducing Windsurf, an AI-powered Integrated Development Environment (IDE) designed to do just that. By seamlessly integrating AI into your workflow, Windsurf promises to help you stay in the co ...

JetBrains warned customers to patch a critical vulnerability that impacts users of its IntelliJ integrated development environment (IDE) apps and exposes GitHub access tokens. Tracked as CVE-2024 ...

A phase 3 non-small cell lung cancer clinical trial of AstraZeneca and Daiichi Sankyo’s TROP2 ADC, Dato-DXd, recently reported seven ILD deaths that were determined to be drug-related.